Cytochrome p-450 polymorphisms and response to clopidogrel.
暂无分享,去创建一个
E. Antman | J. Mega | M. Sabatine | E. Braunwald | R. Hockett | S. Wiviott | Lei-Bin Shen | S. Close | J. Brandt | Joseph R. Walker | W. Macias | J. Walker
[1] M. Keltai,et al. Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON-TIMI 38 trial: a subanalysis of a randomised trial , 2008, The Lancet.
[2] E. Antman,et al. Evaluation of prasugrel compared with clopidogrel in patients with acute coronary syndromes: design and rationale for the TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet InhibitioN with prasugrel Thrombolysis In Myocardial Infarction 38 (TRITON-TIMI 38). , 2006, American heart journal.
[3] K. Winters,et al. Cytochrome P450 3A Inhibition by Ketoconazole Affects Prasugrel and Clopidogrel Pharmacokinetics and Pharmacodynamics Differently , 2007, Clinical pharmacology and therapeutics.
[4] G R Wilkinson,et al. The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. , 1994, The Journal of biological chemistry.
[5] S. Yusuf,et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. , 2001, The New England journal of medicine.
[6] B. Ring,et al. INTERACTIONS OF TWO MAJOR METABOLITES OF PRASUGREL, A THIENOPYRIDINE ANTIPLATELET AGENT, WITH THE CYTOCHROMES P450 , 2006, Drug Metabolism and Disposition.
[7] K. Winters,et al. Effect of ranitidine on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel , 2008, Current medical research and opinion.
[8] P. R. R. Ecurrent,et al. EFFECTS OF CLOPIDOGREL IN ADDITION TO ASPIRIN IN PATIENTS WITH ACUTE CORONARY SYNDROMES WITHOUT ST-SEGMENT ELEVATION , 2001 .
[9] Li Li,et al. Usefulness of left ventricular conic index measured by real-time three-dimensional echocardiography to predict left ventricular remodeling after acute myocardial infarction. , 2008, The American journal of cardiology.
[10] K. Winters,et al. Increased Active Metabolite Formation Explains the Greater Platelet Inhibition With Prasugrel Compared to High-dose Clopidogrel , 2007, Journal of cardiovascular pharmacology.
[11] H. Hod,et al. Clopidogrel Resistance Is Associated With Increased Risk of Recurrent Atherothrombotic Events in Patients With Acute Myocardial Infarction , 2004, Circulation.
[12] P. Hardenbol,et al. Comprehensive assessment of metabolic enzyme and transporter genes using the Affymetrix Targeted Genotyping System. , 2007, Pharmacogenomics.
[13] Jeffrey L. Anderson,et al. 2007 Focused update of the ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. , 2008, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.
[14] S. Iturria,et al. Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel , 2007, Journal of thrombosis and haemostasis : JTH.
[15] M. Young,et al. Determination of the active and inactive metabolites of prasugrel in human plasma by liquid chromatography/tandem mass spectrometry. , 2007, Rapid communications in mass spectrometry : RCM.
[16] K. Winters,et al. Switching directly to prasugrel from clopidogrel results in greater inhibition of platelet aggregation in aspirin-treated subjects , 2008, Platelets.
[17] F. Neumann,et al. Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement. , 2006, Journal of the American College of Cardiology.
[18] D. Flockhart,et al. Clinical Significance of the Cytochrome P450 2C19 Genetic Polymorphism , 2002, Clinical pharmacokinetics.
[19] M. Fromm,et al. Cytochrome P 450 2 C 19 681 G > A Polymorphism and High On-Clopidogrel Platelet Reactivity Associated With Adverse 1-Year Clinical Outcome of Elective Percutaneous Coronary Intervention With Drug-Eluting or Bare-Metal Stents , 2008 .
[20] E. Antman,et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. , 2007, The New England journal of medicine.
[21] Mark W Farmen,et al. Multiplex assay for comprehensive genotyping of genes involved in drug metabolism, excretion, and transport. , 2007, Clinical chemistry.
[22] M. Ingelman-Sundberg,et al. Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects. , 2007, Pharmacology & therapeutics.
[23] A. Bura,et al. 2 C 19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects , 2006 .
[24] Kevin P. Bliden,et al. Clopidogrel for Coronary Stenting Response Variability, Drug Resistance, and the Effect of Pretreatment Platelet Reactivity , 2003, Circulation.
[25] E. Trabetti,et al. Contribution of Gene Sequence Variations of the Hepatic Cytochrome P450 3A4 Enzyme to Variability in Individual Responsiveness to Clopidogrel , 2006, Arteriosclerosis, thrombosis, and vascular biology.
[26] Jeffrey L. Anderson,et al. 2007 focused update of the ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice guidelines. , 2008, Journal of the American College of Cardiology.
[27] M. O’Donoghue,et al. Clopidogrel Response Variability and Future Therapies: Clopidogrel: Does One Size Fit All? , 2006, Circulation.
[28] K. Winters,et al. Effect of Atorvastatin on the Pharmacokinetics and Pharmacodynamics of Prasugrel and Clopidogrel in Healthy Subjects , 2008, Pharmacotherapy.
[29] J. Suh,et al. Increased risk of atherothrombotic events associated with cytochrome P450 3A5 polymorphism in patients taking clopidogrel , 2006, Canadian Medical Association Journal.
[30] Timi Study,et al. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation , 2005 .
[31] C. Macaya,et al. Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives. , 2007, Journal of the American College of Cardiology.
[32] P. Gurbel,et al. Clopidogrel effect on platelet reactivity in patients with stent thrombosis: results of the CREST Study. , 2005, Journal of the American College of Cardiology.
[33] A. Bura,et al. Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. , 2006, Blood.
[34] Magnus Ingelman-Sundberg,et al. Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects. , 2007, Pharmacology & therapeutics.
[35] K. Kim,et al. The Effect of CYP2C19 Polymorphism on the Pharmacokinetics and Pharmacodynamics of Clopidogrel: A Possible Mechanism for Clopidogrel Resistance , 2008, Clinical pharmacology and therapeutics.
[36] M. Fromm,et al. Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents. , 2008, Journal of the American College of Cardiology.